Statement re Sinclair Pharma plc announces appointment of
Jean-Charles Tschudin as non-executive director
Sinclair Pharma plc announces appointment of Jean-Charles Tschudin as
non-executive director
9 November 2007, Godalming, UK: Sinclair Pharma plc (LSE: SPH) is
pleased to announce the appointment of Jean-Charles Tschudin as
non-executive director, effective from 8 November 2007.
Mr Tschudin has extensive experience in the pharmaceutical industry
at a senior executive level. He was recently President and Chief
Operating Officer of Yamanouchi Europe, the largest Japanese company
in Europe (now Astellas). He has also held senior positions at
Johnson & Johnson, Schering-Plough, Syntex and Cardinal Health. Mr
Tschudin is currently non-executive director of SkyePharma PLC.
No disclosures are required under section 9.6.13 of the Listing
Rules.
Andrew Sinclair, founder of Sinclair Pharmaceuticals Ltd in 1973 and
currently a non-executive Director, will not seek re-election at the
Company's Annual General Meeting. Mr Sinclair will maintain an
advisory role with the company and will be appointed Honorary Life
President.
"We are very pleased that Jean-Charles Tschudin will be joining our
Board," said Steve Harris, Chairman of Sinclair Pharma plc. "His
considerable expertise will be invaluable as Sinclair continues its
commercial development, particularly in the expansion of its European
sales and marketing operations. We also thank Andrew Sinclair for
his significant contribution to the company since the management
buy-in in 2000, and we are delighted that he has agreed to maintain
an advisory role with the company indefinitely."
- ends -
For further information please contact:
Sinclair Pharma plc Tel: +44
(0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Zoe McDougall, Director of Communications
Capital MS&L
Annabel O'Connor, Anna Mitchell Tel +44 (0)20
7307 5340
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical
company. It has a growing sales and marketing operation that is
already present in France, Italy, UK, Spain and Portugal, and a
complementary marketing partner network that spans more than 80
countries.
Sinclair has proven expertise in acquiring or developing commercially
attractive and undervalued products, registering these products and
bringing them to market within a short timeframe. The company
focuses on niche therapeutic areas and its current portfolio includes
products for dermatological conditions and oral health.
"Safe Harbor" Statement under the US Private Securities Litigation
Reform Act of 1995: Some or all of the statements in this document
that relate to future plans, expectations, events, performances and
the like are forward-looking statements, as defined in the US Private
Securities Litigation Reform Act of 1995. Actual results of events
could differ materially from those described in the forward-looking
statements due to a variety of factors.
---END OF MESSAGE---